SCHEMBL23947741

SCHEMBL23947741

Cc1nc(N2CCN(C(=O)CCl)CC2)c2c3c(sc2n1)CCCC3

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACA Q13085 1/20 0.74
GPR55 Q9Y2T6 8/20 0.72
CNR1 P21554 7/20 0.72
ALDH1A1 P00352 4/20 0.67
NPSR1 Q6W5P4 2/20 0.67
MEN1 O00255 2/20 0.66
KMT2A Q03164 2/20 0.66
LMNA P02545 3/20 0.62
HPGD P15428 3/20 0.62
MAPK1 P28482 2/20 0.62
KDM4E B2RXH2 2/20 0.60
ALOX15 P16050 1/20 0.60
TSHR P16473 1/20 0.60
HSD17B10 Q99714 1/20 0.60
NPC1 O15118 1/20 0.60
POLB P06746 1/20 0.60
RAB9A P51151 1/20 0.60
ATM Q13315 1/20 0.60
HTR6 P50406 1/20 0.59
CNR2 P34972 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29763665 1.00 ACACA (0.74) ACACAGPR55CNR1ALDH1A1NPSR1
SCHEMBL23947763 0.87 MEN1 (0.75) ACACAGPR55CNR1ALDH1A1NPSR1
SCHEMBL29763666 0.87 MEN1 (0.75) ACACAGPR55CNR1ALDH1A1NPSR1
SCHEMBL23947717 0.84 MEN1 (0.62) ACACAGPR55CNR1ALDH1A1NPSR1
SCHEMBL29763659 0.84 MEN1 (0.62) ACACAGPR55CNR1ALDH1A1NPSR1
SCHEMBL23947720 0.82 ALDH1A1 (0.65) ACACAGPR55CNR1ALDH1A1NPSR1
SCHEMBL29763672 0.82 ALDH1A1 (0.65) ACACAGPR55CNR1ALDH1A1NPSR1
SCHEMBL29763674 0.80 ALDH1A1 (0.63) ACACAGPR55CNR1ALDH1A1NPSR1
SCHEMBL23947737 0.80 ALDH1A1 (0.63) ACACAGPR55CNR1ALDH1A1NPSR1
SCHEMBL31691578 0.77 GPR55 (1.00) ACACAGPR55CNR1ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230047626-A1 SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS THE TRUSTEES OF INDIANA UNIVERSITY 2023-02-16 US disclosed
US-20220142973-A1 SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS THE TRUSTEES OF INDIANA UNIVERSITY 2022-05-12 US disclosed
WO-2021212010-A2 SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS THE TRUSTEES OF INDIANA UNIVERSITY (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047626-A1 SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS TP53, EIF2AK2, POLI ACACA 4102/4885GPR55 4199/4885CNR1 4715/4885
US-20220142973-A1 SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS TP53, EIF2AK2, POLI ACACA 4102/4885GPR55 4199/4885CNR1 4715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.